Zogenix Inc (ZGNX) 9.16 $ZGNX Zogenix Announces

New Post Public Reply Private Reply Replies (0) Message Board
Stock_Tracker
Zogenix Inc (ZGNX) 9.16 $ZGNX

Zogenix Announces Initiation of Multi-National Phase 3 Clinical Trial for ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jun 07, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the second Phase 3 clinical trial, a multi-national study (Study 1502), for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome. ZX008 is designated as an orphan drug in both the U.S. and Europe, and received Fast Track designation in the U.S., for the treatment of Dravet syndrome.
ZGNX: 9.16 (+0.03)

Zogenix to Participate in Jefferies 2016 Healthcare Conference
GlobeNewswire - Tue May 31, 7:00AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, will present a corporate update at the Jefferies 2016 Healthcare Conference, which is being held in New York, NY, June 7-10, 2016.
ZGNX: 9.16 (+0.03)

Nordic Nanovector ASA: New Board Members Elected Bringing Further Expertise in the Development and Commercialization of Innovative Cancer Therapies
BusinessWire - Mon May 23, 12:17AM CDT
The annual general meeting of Nordic Nanovector ASA on 19 May elected two new board members, further strengthening the base of international experience as well as oncology/haematology, life science and commercialization expertise of the company's board. Dr Renee P Tannenbaum, Pharm. D and Jean-Pierre Bizzari, MD, were elected as new board members. Founder Dr Roy Hartvig Larsen steps down from the board to focus on new research projects.
ZGNX: 9.16 (+0.03)

Zogenix reports 1Q loss
Automated Insights - Tue May 10, 4:20PM CDT
EMERYVILLE, Calif. (AP) _ Zogenix Inc. (ZGNX) on Tuesday reported a loss of $10.4 million in its first quarter.
ZGNX: 9.16 (+0.03)

Zogenix Provides Corporate Update and Reports First Quarter 2016 Financial Results
GlobeNewswire - Tue May 10, 3:01PM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the first quarter ended March 31, 2016.
ZGNX: 9.16 (+0.03)

Zogenix Announces New Efficacy and Safety Data on ZX008 for Treatment of Seizures in Dravet Syndrome
GlobeNewswire - Thu May 05, 7:01AM CDT
Patient and Caregiver Sleep Quality and Quality of Life Data Reported for First Time
ZGNX: 9.16 (+0.03)

Zogenix to Release First Quarter 2016 Financial Results and Host Conference Call and Webcast on May 10
GlobeNewswire - Tue May 03, 7:00AM CDT
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that it will report its financial results for the first quarter ended March 31, 2016 after the market close, and will host a corporate update conference call and webcast on Tuesday, May 10, at 4:30 PM Eastern Time.
ZGNX: 9.16 (+0.03)

New Data on Zogenix's ZX008 for Dravet Syndrome to be Presented at 14th International Child Neurology Congress
GlobeNewswire - Thu Apr 21, 7:03AM CDT
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that new data on ZX008 (low-dose fenfluramine) will be presented at the 14 International Child Neurology Congress (ICNC), which will take place in Amsterdam, The Netherlands, from May 1 - 5, 2016. The presentation will report the latest efficacy and safety data from the prospectively followed cohort of patients treated with ZX008 for Dravet syndrome, a rare and catastrophic form of childhood epilepsy. In addition, for the first time, data will be presented on patient and caregiver sleep quality and quality of life.
ZGNX: 9.16 (+0.03)

Commit To Buy Zogenix At $8, Earn 8.1% Annualized Using Options
StockOptionsChannel.com - Tue Apr 12, 10:38AM CDT
Investors eyeing a purchase of Zogenix Inc. shares, but tentative about paying the going market price of $10.31/share, might benefit from considering selling puts among the alternative strategies at their disposal.
ZGNX: 9.16 (+0.03)

Cipher Pharmaceuticals Proposes Adding Rosemary A. Crane and Dr. Renee P. Tannenbaum To Board of Directors
CNW Group - Thu Apr 07, 6:00AM CDT
Cipher Pharmaceuticals Inc. (NASDAQ:CPHR; TSX:CPH) ("Cipher" or "the Company" today announced that Rosemary A. (Rose) Crane and Dr. Renee P. Tannenbaum, two pharmaceutical industry leaders, are being proposed for election to Cipher's Board of Directors at the Company's Annual and Special Meeting on May 5, 2016.
CPH.TO: 6.58 (+0.03), MELA: 1.12 (+0.01), ZGNX: 9.16 (+0.03), CPHR: 4.95 (-0.05), ABBV: 66.62 (+0.39), TEVA: 53.98 (+0.48)

Zogenix Provides Corporate Update and Reports Fourth Quarter and Full-Year 2015 Financial Results
GlobeNewswire - Thu Mar 10, 3:03PM CST
Zogenix, Inc. (NASDAQ:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today provided a corporate update and announced financial results for the fourth quarter and year ended December 31, 2015.
ZGNX: 9.16 (+0.03)

Zogenix, Inc. Shares Galloped 15% Higher in February -- Here's Why
Sean Williams, The Motley Fool - Motley Fool - Thu Mar 10, 2:41PM CST
Image source: Centers for Disease Control and Prevention.  What: Shares of Zogenix , a small-cap clinical-stage drug developer aiming to discover therapies to treat central nervous system disorders, galloped higher by 15% in February, based on...
GWPH: 95.75 (+1.43), ZGNX: 9.16 (+0.03)

Zogenix to Participate in LEERINK Partners 5th Annual Global Healthcare Conference
GlobeNewswire - Wed Feb 03, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced that Stephen J. Farr, Ph.D., President and CEO, and Bradley S. Galer, M.D., Executive Vice President and CMO, will present a corporate update at the LEERINK Partners 5 Annual Global Healthcare Conference in New York, NY, on February 10, 2016.
ZGNX: 9.16 (+0.03)

Bipolar Disorder (Manic Depression) - Pipeline Review
M2 - Mon Feb 01, 4:54AM CST
Research and Markets (http://www.researchandmarkets.com/research/f9ppsp/bipolar_disorder) has announced the addition of the "Bipolar Disorder (Manic Depression) - Pipeline Review, H2 2015" report to their offering. This report provides comprehensive information on the therapeutic development for Bipolar Disorder (Manic Depression), complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Bipolar Disorder (Manic Depression) and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Key Topics Covered: - Introduction - Bipolar Disorder (Manic Depression) Overview - Therapeutics Development - Pipeline Products for Bipolar Disorder (Manic Depression) - Overview - Pipeline Products for Bipolar Disorder (Manic Depression) - Comparative Analysis - Bipolar Disorder (Manic Depression) - Therapeutics under Development by Companies - Bipolar Disorder (Manic Depression) - Therapeutics under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Pipeline Products Glance - Late Stage Products - Clinical Stage Products - Early Stage Products - Bipolar Disorder (Manic Depression) - Products under Development by Companies - Bipolar Disorder (Manic Depression) - Products under Investigation by Universities/Institutes - Bipolar Disorder (Manic Depression) - Companies Involved in Therapeutics Development Companies Mentioned: - Aequus Pharmaceuticals Inc. - ANP Technologies, Inc. - AstraZeneca Plc - Convergence Pharmaceuticals Ltd. - D-Pharm Ltd. - Delpor, Inc. - Intas Pharmaceuticals Ltd. - Intra-Cellular Therapies, Inc. - Johnson & Johnson - KemPharm, Inc. - Neurocrine Biosciences, Inc. - Omeros Corporation - Otsuka Holdings Co., Ltd. - Pfizer Inc. - Reviva Pharmaceuticals Inc. - SK Biopharmaceuticals Co., Ltd. - Sumitomo Dainippon Pharma Co., Ltd. - Teva Pharmaceutical Industries Limited - Zogenix, Inc. - Zysis Limited For more information visit http://www.researchandmarkets.com/research/f9...r_disorder
JNJ: 125.11 (-0.12), NBIX: 51.05 (+0.82), KMPH: 4.19 (-0.03), ZGNX: 9.16 (+0.03), PFE: 37.05 (+0.16), AZN: 33.93 (-0.21), TEVA: 53.98 (+0.48), ITCI: 40.75 (-0.05), OMER: 11.92 (+0.16)

Will Insiders Be Tempted To Buy More ZGNX At The New 52-Week Low?
TheOnlineInvestor.com - Wed Jan 20, 12:14PM CST
In trading on Wednesday, shares of Zogenix Inc. touched a new 52-week low of $9.02/share.
ZGNX: 9.16 (+0.03)

Zogenix Receives Fast Track Designation From FDA for Development of ZX008 in Dravet Syndrome
GlobeNewswire - Tue Jan 19, 7:09AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced receipt of Fast Track designation from the U.S. Food and Drug Administration (FDA) for the development program for the Company's investigational product, ZX008, as a treatment of seizures associated with Dravet syndrome, a rare and catastrophic form of childhood epilepsy.
ZGNX: 9.16 (+0.03)

Zogenix, Inc Gained 29% in 2015 -- Here's Why
Brian Feroldi, The Motley Fool - Motley Fool - Thu Jan 14, 10:59AM CST
What:  2015 was a great year to be a Zogenix shareholder. The clinical-stage biopharmaceutical company's stock soared more than 29% higher during the year, according to data from S&P Capital IQ . So what: The year was filled with...
PTX: 0.61 (+0.02), ZGNX: 9.16 (+0.03)

Healthcare Sector Equities under Review -- Amarin, Arrowhead Research, Zogenix, and PetMed Express
ACCESSWIRE - Wed Jan 13, 7:02AM CST
NEW YORK, NY / ACCESSWIRE / January 13, 2016 / Park Lane Advisor has initiated coverage on the following equities: Amarin Corporation PLC (NASDAQ: AMRN), Arrowhead Research Corporation (NASDAQ: ARWR), Zogenix Inc. (NASDAQ: ZGNX), and PetMed Express Inc. (NASDAQ: PETS). Free research report on Amarin can be accessed at http://www.parklaneadvisor.com/ On Tuesday, January 12, 2016, the NASDAQ Composite ended at 4,685.92, up 1.03%, the Dow Jones Industrial Average advanced 0.72%, to finish the day at 16,516.22, and the S&P 500 closed at 1,938.68, up 0.78%. The gains were broad based as six out of nine sectors ended the session in positive. Register for your complimentary reports at the links given below.
PETS: 20.61 (-0.12), ARWR: 6.03 (+0.07), ZGNX: 9.16 (+0.03), AMRN: 2.92 (+0.27)

Zogenix Announces Initiation of Phase 3 Program for ZX008 in Dravet Syndrome
GlobeNewswire - Mon Jan 11, 7:00AM CST
Zogenix, Inc. (Nasdaq:ZGNX), a pharmaceutical company developing therapies for the treatment of central nervous system (CNS) disorders, today announced the initiation of the first Phase 3 clinical trial for the Company's lead product candidate, ZX008, as an adjunctive treatment of seizures in children with Dravet syndrome.
ZGNX: 9.16 (+0.03)

Scroll down for more posts ▼

Top 10 Most Recent News Articles

Anthropic's Leveraged ETFs Arrive After Wild Debut

Updated Category News Views 360

Nothing says a feverish new listing quite like leveraged products lining up before the opening-week confetti has settled. Anthropic priced its IPO at $83 on November 18, raised roughly $81.3 billion, then opened Nasdaq trading at $111.50 on November 19. That is an enormous gap between IPO price and first trade, and it tells investors the obvious thing: plenty of appetite...

Continue Reading
Newegg’s GIGABYTE Event Is Brand Work, Not a Catalyst

Updated Category News Views 251

A 2,300-square-foot room can tell a retailer plenty about its tribe. On November 21, Newegg is turning its Diamond Bar Gamer Zone into the home base for GIGABYTE’s AORUS VS40 celebration, a free five-hour event marking the hardware maker’s 40th anniversary. There will be 1v1 VALORANT and League of Legends contests, demo stations, raffles, anniversary merchandise, food...

Continue Reading
PHONO's 150 MW RE+ Win Tests Its U.S. Solar Staying Power

Updated Category News Views 41

A trade-show order book is not cash in the bank, but 150 MW is still a number worth circling in red. PHONO used RE+ 2026 in Las Vegas, held November 17 through 19, to celebrate 20 years in business, parade its solar and storage lineup, and announce new U.S. orders. In a solar market that has become touchier about provenance, compliance and delivered economics, the company...

Continue Reading
Persistent Dry Eye Symptoms Call for a Closer Look

Updated Category News Views 120

Eyes can turn into a stubborn little nuisance long before people realize something more complicated is going on. A bottle of artificial tears is easy to grab, cheap enough, and often perfectly sensible for a rough day of screens, wind, reading, or air conditioning. But Dr. Harlan Snyder’s point is the one worth sitting with: when dryness keeps barging back despite...

Continue Reading
Kinross Lawsuit Puts Round Mountain Claims Under Fire

Updated Category News Views 128

A mine can swallow a rosy forecast faster than any spreadsheet admits. That is the ugly center of the proposed securities class action involving Kinross Gold: not merely that production guidance came down, but the allegation that investors were sold too much confidence before the operational reality at Round Mountain Phase S surfaced. NYSE:KGC dropped from $27.62 on...

Continue Reading
Fluence Investors Face a November 27 Litigation Clock

Updated Category News Views 187

Six calendar squares are all that separate eligible Fluence investors from the November 27, 2026 lead-plaintiff deadline. That is not much time to locate trade confirmations, calculate losses, and decide whether taking a larger role in a securities case makes sense. The lawsuit is not a verdict, and anybody pretending otherwise is selling smoke. But the underlying...

Continue Reading
Mission Inn’s Lights Enter a Tender New Ownership Era

Updated Category News Views 95

A holiday spectacle can outlive the hands that hung its first bulb. Riverside is about to test that truth in public, under millions of tiny lights and the very large shadow of a family departure. The Mission Inn Festival of Lights returns in 2026 without Kelly and Duane Roberts as hotel owners for the first time in more than three decades. Duane Roberts died in 2025, the...

Continue Reading
Fractional CIOs Bring Order to Growing Technology Chaos

Updated Category News Views 175

A company can outgrow its technology habits long before anyone notices the smoke. One day the owner is approving another software subscription, the office manager is chasing an internet provider, and the tech person is putting out password fires. None of that looks dramatic in isolation. Together, it is a business operating without a map. That is the useful point in the...

Continue Reading
Isar’s Nova Scotia Pad Build Gives MAXQ a Real Test

Updated Category News Views 229

Concrete work is where space ambition stops being a brochure. Isar Aerospace has taken operational responsibility for its dedicated launch infrastructure at Spaceport Nova Scotia, and construction is beginning on the Canadian launch pad it will use. For Maritime Launch Services, this is the sort of update that deserves more than the usual starry-eyed applause. A Site...

Continue Reading
Ajman Memory Gives Heritage a Durable Digital Backbone

Updated Category News Views 79

Archives usually get applause only after somebody realizes a piece of history has vanished. Ajman is trying to skip that miserable part. During the Ajman Media Forum 2026, held November 18 and 19 at the Emirates Hospitality Centre, the emirate launched Ajman Memory, a project built to collect, document and preserve photographs, papers and video recording its development....

Continue Reading

Top 5 Most Recently Viewed Articles

Marqeta Class Action Lawsuit: Investor Rights Alert

Updated Category News Views 115

Investors Take Action: Marqeta, Inc. Securities Lawsuit In an important update for shareholders of Marqeta, Inc. (NASDAQ: MQ), it has been brought to attention by Kahn Swick & Foti, LLC that investors who have incurred losses exceeding $100,000 have until a specific deadline to file lead plaintiff applications in a key class action lawsuit. Understanding the Class Action...

Continue Reading
Emerging Strategies for the Chronic Refractory Cough Market

Updated Category News Views 266

Chronic Refractory Cough Market Overview The chronic refractory cough market is emerging as a significant opportunity for pharmaceutical companies. As analyzed, the market size is poised for considerable growth due to various factors, including rising disease prevalence and a corresponding increase in approved product availability. Notably, several innovative therapies...

Continue Reading
Hydreight Technologies: A Rising Star in Healthcare Services

Updated Category News Views 185

Hydreight Technologies Achieves Major Recognition In the fast-paced world of technology and healthcare, Hydreight Technologies Inc. has made an impressive mark, securing the spot of No. 77 on a prestigious list of the fastest-growing companies in North America. This ranking, part of the 2025 Deloitte Technology Fast 500™, positions Hydreight among elite innovators and...

Continue Reading
Empowering Communities: PHFA's $75 Million Housing RFP Launch

Updated Category News Views 90

Introducing the New PHARE Funding Opportunities for Housing The Pennsylvania Housing Finance Agency (PHFA) is excited to announce a new funding opportunity that aims to improve housing availability and affordability across the state. This initiative encourages organizations to submit proposals for projects designed to address urgent housing challenges in their...

Continue Reading
Investigating Investor Claims Against Polestar Automotive

Updated Category News Views 114

Investigation of Investor Claims Against Polestar Automotive Faruqi & Faruqi, LLP, a prominent national securities law firm, is initiating an investigation into potential claims for investors of Polestar Automotive Holding UK PLC. If you've experienced financial losses linked to Polestar, now is the time to explore your options and safeguard your rights. Understanding...

Continue Reading